| Aug 30 |
Can-Fite BioPharma files to sell 1.77B shares of common stock for holders
|
| Aug 30 |
Is Can-Fite BioPharma Ltd. (CANF) The Best Rated Penny Stock To Buy According to Analysts?
|
| Aug 29 |
Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.32M
|
| Aug 29 |
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
|
| Aug 9 |
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
| Aug 8 |
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
|
| Jul 29 |
Can-Fite Provides Namodenoson Patent Update
|
| Jul 17 |
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8
|
| Jul 11 |
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
|
| Jul 1 |
Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson
|
